Adam Crystal, who serves as President of Research and Development at Tango Therapeutics, Inc. (NASDAQ:TNGX), completed a set of transactions on March 25, 2026, that included the sale of common stock and the exercise of stock options.
Citing company filings, Crystal sold 12,000 shares of Tango common stock for aggregate proceeds of approximately $241,320. The shares changed hands at prices between $20.00 and $20.27 per share.
Concurrently, Crystal exercised options enabling the purchase of 12,000 shares of Tango common stock at an exercise price of $5.20 per share, for a total exercise cost of $62,400. The filings indicate both the sale and the option exercise were executed under a pre-arranged Rule 10b5-1 trading plan that Crystal adopted on October 27, 2025.
After these moves, Crystal directly holds 112,622 shares of Tango Therapeutics.
Market signals around TNGX are mixed. According to InvestingPro Tips, the stock has produced strong returns over the last one- and three-month periods, though technical indicators such as the relative strength index suggest the shares are in overbought territory.
On the financial front, Tango Therapeutics reported a net loss of $38.7 million for the fourth quarter of 2025 and a full-year net loss of $101.6 million for 2025.
Despite recent losses, several research firms have offered constructive commentary and revised valuations. Stifel raised its price target for Tango to $24, citing progress in PRMT5 inhibitors and developments in RAS(ON) combinations that it sees as beneficial for the company’s pancreatic cancer programs. Jefferies also increased its price target to $18, pointing to Tango’s supply agreement with ERAS for pan-RAS as a notable factor. Mizuho entered coverage with an outperform rating and a $19 price target, highlighting the potential of Tango’s lead oncology program, vopimetostat. Separately, Stifel reiterated a Buy rating while maintaining a $15 price target, emphasizing the firm’s view of Tango’s strategic priorities and upcoming pipeline updates.
These analyst moves, combined with the insider activity, paint a picture of continuing interest from the sell-side even as the company reported sizable losses in 2025. Investors tracking TNGX may weigh the insider transactions, technical indicators, recent financial performance, and the range of analyst views when considering the stock.
For readers seeking more detailed metrics and the suite of analyst insights referenced by InvestingPro, the InvestingPro platform provides a Pro Research Report and additional ProTips.